Javascript must be enabled to continue!
SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment
View through CrossRef
Abstract
T cell exhaustion represents one of the most pervasive strategies tumors employ to circumvent the immune system. Although repetitive, cognate TCR signaling is recognized as the primary driving force behind this phenomenon, and it remains unknown what other forces drive T cell exhaustion in the tumor microenvironment (TME). In this study, we show that activation of the self-ligand SLAMF7 immune receptor on T cells induced STAT1 and STAT3 phosphorylation, expression of multiple inhibitory receptors, and transcription factors associated with T cell exhaustion. Analysis of The Cancer Genome Atlas revealed that SLAMF7 transcript levels were strongly correlated with various inhibitory receptors and that high SLAMF7 expression was indicative of poor survival in clear cell renal cell carcinoma (ccRCC). Targeted reanalysis of a CyTOF dataset, which profiled the TME in 73 ccRCC patients, revealed cell-type–specific SLAMF7 expression patterns, strong correlations between exhausted T cells and SLAMF7+ tumor-associated macrophages (TAMs), and a unique subset of SLAMF7highCD38high TAMs. These SLAMF7highCD38high TAMs showed the strongest correlations with exhausted T cells and were an independent prognostic factor in ccRCC. Confirmatory ex vivo coculture studies validated that SLAMF7–SLAMF7 interactions between murine TAMs and CD8+ T cells induce expression of multiple inhibitory receptors. Finally, mice lacking SLAMF7 show restricted growth of B16-F10 tumors, and CD8+ T cells from these mice express less PD-1 and TOX and exhibited an impaired ability to progress through the exhaustion developmental trajectory to terminal exhaustion. These findings suggest that SLAMF7 might play an important role in modulating T cell function in the TME.
Oxford University Press (OUP)
Title: SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment
Description:
Abstract
T cell exhaustion represents one of the most pervasive strategies tumors employ to circumvent the immune system.
Although repetitive, cognate TCR signaling is recognized as the primary driving force behind this phenomenon, and it remains unknown what other forces drive T cell exhaustion in the tumor microenvironment (TME).
In this study, we show that activation of the self-ligand SLAMF7 immune receptor on T cells induced STAT1 and STAT3 phosphorylation, expression of multiple inhibitory receptors, and transcription factors associated with T cell exhaustion.
Analysis of The Cancer Genome Atlas revealed that SLAMF7 transcript levels were strongly correlated with various inhibitory receptors and that high SLAMF7 expression was indicative of poor survival in clear cell renal cell carcinoma (ccRCC).
Targeted reanalysis of a CyTOF dataset, which profiled the TME in 73 ccRCC patients, revealed cell-type–specific SLAMF7 expression patterns, strong correlations between exhausted T cells and SLAMF7+ tumor-associated macrophages (TAMs), and a unique subset of SLAMF7highCD38high TAMs.
These SLAMF7highCD38high TAMs showed the strongest correlations with exhausted T cells and were an independent prognostic factor in ccRCC.
Confirmatory ex vivo coculture studies validated that SLAMF7–SLAMF7 interactions between murine TAMs and CD8+ T cells induce expression of multiple inhibitory receptors.
Finally, mice lacking SLAMF7 show restricted growth of B16-F10 tumors, and CD8+ T cells from these mice express less PD-1 and TOX and exhibited an impaired ability to progress through the exhaustion developmental trajectory to terminal exhaustion.
These findings suggest that SLAMF7 might play an important role in modulating T cell function in the TME.
Related Results
SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity
SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity
Abstract
Background
Multiple sclerosis (MS) is a chronic, debilitating condition characterized by CNS autoimmunity stemming from a complex etiology ...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
Multiple myeloma (MM) is a common hematological malignancy that has fostered several new therapeutic approaches to combat newly diagnosed or relapsed MM. While the field has advanc...
Supplementary Data from Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
Supplementary Data from Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
<p>Supplementary Methods, Supplementary Figures S1-S15 Fig. S1. Purification and binding specificity of MV-encoded BiTEs. (A) Purification of MV-expressed BiTEs. Vero cells w...
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Abstract
Introduction
Sacrococcygeal teratoma (SCT) is a rare embryonal tumor that occurs in the sacrococcygeal region, with an incidence of about 1 in 35,000 to 40,000 live births...
Tumor endothelial cells accelerate tumor metastasis
Tumor endothelial cells accelerate tumor metastasis
Tumor metastasis is the main cause of cancer‐related death. Understanding the molecular mechanisms underlying tumor metastasis is crucial to control this fatal disease. Several mol...
Abstract 1596: Tumor-derived RAC1A159V gain-of-function mutation promotes an immunosuppressive tumor microenvironment and represses response to immune checkpoint inhibitors
Abstract 1596: Tumor-derived RAC1A159V gain-of-function mutation promotes an immunosuppressive tumor microenvironment and represses response to immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) specifically target immune checkpoint molecules and activate cytotoxic T lymphocytes (CTLs) to kill cancer cells and have seen great success in ...
Kanser İlişkili Yeni Hedef Molekül SLAMF7
Kanser İlişkili Yeni Hedef Molekül SLAMF7
Kanser hücre için kontrolsüz büyüme getirisi sağlayan, geniş
bir çeşitlilik ve karmaşık süreçlerle karakterize edilir.
Hastalığın erken teşhisi, prognozun iyileştirilmesi, sağkalım...

